Bioanalytical Methods for MEDI3726 Assessment

This document is a research article that presents multifaceted bioanalytical methods developed for the comprehensive pharmacokinetic (PK) and catabolic assessment of MEDI3726, an antibody-drug conjugate targeting prostate-specific membrane antigen (PSMA). The article outlines the challenges associated with the bioanalytical characterization of complex biotherapeutics like MEDI3726, which is comprised of a humanized IgG1 antibody conjugated to the warhead tesirine. The authors detail the bioanalytical strategy, which includes quantification of Total ADC, Total IgG, and Free Warhead concentrations. They describe the development and validation of an array of four bioanalytical assays that detect six different surrogate analyte classes representing at least fourteen unique species. The findings indicate the importance of understanding the PK and catabolism of MEDI3726 for its efficacy and safety in clinical settings. The document also references the structural characteristics of MEDI3726 and its implications for therapeutic intervention in metastatic castration-resistant prostate cancer (mCRPC).